Can a biologic drug safely tame Back-Joint inflammation? a Real-World trial investigates

NCT ID NCT07737730

Not yet recruiting Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tracks the safety of secukinumab, a biologic injection, in Indian adults with axial spondyloarthritis — a group of inflammatory conditions that cause back pain and stiffness. Over 16 weeks, researchers will monitor side effects and disease activity in about 60 participants treated in routine clinical practice. The goal is to see how well the drug is tolerated outside of controlled trial settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: secukinumab (a biologic drug given as a subcutaneous injection in a pre-filled pen)
What this could lead to: If the results are reassuring, this could support the safe use of secukinumab for managing axial spondyloarthritis in Indian patients.
What could go wrong: This is an observational study with no control group, so it cannot prove cause and effect. Side effects may still occur, and the 16-week follow-up is short.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis Axial Spondyloarthritis Non-Radiographic Axial Spondyloarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS AXIAL SPONDYLOARTHRITIS NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.